

**PERCENT SUSCEPTIBILITY- COMMONLY ISOLATED BACTERIA AT YRMC (FROM INPATIENT AND OUTPATIENT ISOLATES COLLECTED 1/1/2023 TO 6/30/2023)**

<b>ORGANISM</b>	# Isolates	Amikacin	Ampicillin	Ampicillin/sulbactam (Unasyn)	Cefazolin	Cefepime	Ceftazidime	Ceftriaxone	Clindamycin	Daptomycin	Doxycycline	Ertapenem (Invanz)	Gentamicin	Levofloxacin (Levaquin)	Meropenem (Merrem)	Nafcillin/oxacillin	Nitrofurantoin (Macrobid®) (urine only)	Penicillin	Piperacillin/tazobactam (Zosyn)	Sulfa/trimethoprim (Bactrim, Septra)	Tetracycline	Tobramycin	Vancomycin
<b>GRAM-POSITIVE BACTERIA</b>																							
Enterococcus faecalis	367		100							100			71 <sup>s</sup>				100	98					100
Enterococcus faecium	65									100			81 <sup>s</sup>										64
Staphylococcus aureus	395				64				67	100	97		93	66		64	100			98	91		100
Streptococcus pneumoniae**	27							100	94					100	95			100		74	95		100
<b>GRAM-NEGATIVE BACTERIA</b>																							
Enterobacter cloacae	93	100				93	81	74				87	99	91	97				80	93		97	
Escherichia coli	1904	100	49	58		87	86	86				100	88	69	100		98		97	69		86	
Klebsiella pneumoniae	414	100		74		87	87	87				100	94	86	99				92	85		93	
Proteus mirabilis	229	99	79	83		98	100	100				99	89	70					100	80		87	
Pseudomonas aeruginosa	263	99				93	93						95	81	94				89			98	

**Note: Only antibiotic susceptibility >30% included ; tested on BD Phoenix**

**VRE rate:** 36% of Enterococcus faecium are resistant to vancomycin

**MRSA rate:** 36%

**Extended-spectrum beta-lactamase (ESBL) rate:** 14% of E. coli from all sources and 13% Klebsiella pneumonia from all source are ESBL

\*Meningitis isolates

<sup>s</sup> For synergy use only

^Ertapenem susceptibility